2024
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter study
2023
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.Peer-Reviewed Original ResearchConceptsDeterioration of eGFRHeart failureSafety outcomesKidney functionTreatment groupsTime-updated Cox proportional hazards modelsSodium-glucose cotransporter 2 inhibitorsComorbid chronic kidney diseaseCox proportional hazards modelPrimary composite outcomeChronic kidney diseaseCotransporter 2 inhibitorsEffect of dapagliflozinGlomerular filtration rateProportional hazards modelLives of patientsDAPA-HFDrug discontinuationCardiovascular deathCardiovascular outcomesStudy drugChronic heartComposite outcomeDapagliflozin treatmentPrimary outcomeDapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.Peer-Reviewed Original ResearchConceptsBaseline kidney functionKidney composite outcomeEffect of dapagliflozinEjection fractionHeart failureKidney outcomesComposite outcomePrimary outcomeKidney functionKidney diseaseSodium-glucose cotransporter 2 inhibitorsBaseline eGFR categoryBaseline kidney diseaseBenefit of dapagliflozinComposite kidney outcomeHeart Failure TrialReduced ejection fractionCotransporter 2 inhibitorsHeart failure eventsGlomerular filtration rateOverall incidence rateOverall event rateLives of patientsTreatment effectsEGFR categories
2021
Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME
Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.Peer-Reviewed Original Research
2020
132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.Peer-Reviewed Original ResearchBoehringer Ingelheim-LillyCV deathBoehringer Ingelheim PharmaceuticalsMundipharma InternationalBaseline characteristicsNovo Nordisk A/SJanssen PharmaceuticalsEli LillyRisk reductionEMPA-REG OUTCOMEKDIGO risk categoriesPredictive baseline factorsRenal hemodynamic effectsSerious adverse eventsAdvanced kidney diseaseAdvisory PanelGlomerular filtration rateJanssen Scientific AffairsMultivariate logistic regressionDeath risk reductionNovo NordiskDiuretic therapyEGFR declineSanofi GenzymeCV disease